The TNF cytokine family: One track in a road paved by many

Cytokine

Volumn 63, Issue 3, 2013, Pages 225-229

  Wallach, David ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Apoptosis; Caspase 8; NF kappa B; Signaling; TNF

Indexed keywords

ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOTOXIN; ONERCEPT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; BINDING AFFINITY; CELL DEATH; CONFORMATIONAL TRANSITION; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LIGAND BINDING; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

APOPTOSIS; CASPASE-8; NF KAPPA B; SIGNALING; TNF;

ANIMALS; APOPTOSIS; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTORS;

EID: 84881612886     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.05.027     Document Type: Article

References (34)

1. Old L.J. Tumor necrosis factor (TNF). Science 1985, 230:630-632.
2. Menkin V. Newer Concepts of Inflammation 1948, Charles C Thomas, Springfield.
3. Granger G.A., Kolb W.P. Lymphocyte in vitro cytotoxicity: mechanisms of immune and non-immune small lymphocyte mediated target L cell destruction. J Immunol 1968, 101:111-120.
4. Ruddle N.H., Waksman B.H. Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. III. Analysis of mechanism. J Exp Med 1968, 128:1267-1279.
5. Beutler B., Greenwald D., Hulmes J.D., Chang M., Pan Y.C., Mathison J., et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985, 316:552-554.
6. Wallach D. Regulation of susceptibility to natural killer cells' cytotoxicity and regulation of HLA synthesis: differing efficacies of alpha, beta, and gamma interferons. J Interferon Res 1982, 2:329-338.
7. Wallach D. Interferon-induced resistance to the killing by NK cells: a preferential effect of IFN-gamma. Cell Immunol 1983, 75:390-395.
8. Wallach D., Fellous M., Revel M. Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature 1982, 299:833-836.
9. Wallach D., Hahn T. Enhanced release of lymphotoxins by interferon-treated cells. Cell Immunol 1983, 76:390-396.
10. Wallach D. Preparations of lymphotoxin induce resistance to their own cytotoxic effect. J Immunol 1984, 132:2464-2469.
11. Holtmann H., Wallach D. Down regulation of the receptors for tumor necrosis factor by interleukin 1 and 4 beta-phorbol-12-myristate-13-acetate. J Immunol 1987, 139:1161-1167.
12. Holtmann H., Hahn T., Wallach D. Interrelated effects of tumor necrosis factor and interleukin 1 on cell viability. Immunobiology 1988, 177:7-22.
13. Hahn T., Toker L., Budilovsky S., Aderka D., Eshhar Z., Wallach D. Use of monoclonal antibodies to a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein. Proc Natl Acad Sci USA 1985, 82:3814-3818.
14. Engelmann H., Holtmann H., Brakebusch C., Avni Y.S., Sarov I., Nophar Y., et al. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem. 1990, 265:14497-14504.
15. Israel S., Hahn T., Holtmann H., Wallach D. Binding of human TNF-alpha to high-affinity cell surface receptors: effect of IFN. Immunol Lett 1986, 12:217-224.
16. Engelmann H., Aderka D., Rubinstein M., Rotman D., Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989, 264:11974-11980.
17. Engelmann H., Novick D., Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990, 265:1531-1536.
18. Nophar Y., Kemper O., Brakebusch C., Engelmann H., Zwang R., Aderka D., et al. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R cloned using amino acid data of its soluble form, encodes for both the cell surface and a soluble form of the receptor. EMBO J 1990, 9:3269-3278.
19. Brakebusch C., Nophar Y., Kemper O., Engelmann H., Wallach D. Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor. EMBO J. 1992, 11:943-950.
20. Brakebusch C., Varfolomeev E.E., Batkin M., Wallach D. Structural requirements for inducible shedding of the p55 tumor necrosis factor receptor. J Biol Chem 1994, 269:32488-32496.
21. Boldin M.P., Mett I.L., Varfolomeev E.E., Chumakov I., Shemer A.Y., Camonis J.H., et al. Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem 1995, 270:387-391.
22. Boldin M.P., Varfolomeev E.E., Pancer Z., Mett I.L., Camonis J.H., Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995, 270:7795-7798.
23. Boldin M.P., Goncharov T.M., Goltsev Y.V., Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996, 85:803-815.
24. Malinin N.L., Boldin M.P., Kovalenko A.V., Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 1997, 385:540-544.
25. Zhang S.Q., Kovalenko A., Cantarella G., Wallach D. Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity 2000, 12:301-311.
26. Ramakrishnan P., Wang W., Wallach D. Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity 2004, 21:477-489.
27. Kovalenko A., Chable-Bessia C., Cantarella G., Israel A., Wallach D., Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003, 424:801-805.
28. Goltsev Y.V., Kovalenko A.V., Arnold E., Varfolomeev E.E., Brodianskii V.M., Wallach D. CASH, a novel caspase homologue with death effector domains. J Biol Chem 1997, 272:19641-19644.
29. Varfolomeev E.E., Schuchmann M., Luria V., Chiannilkulchai N., Beckmann J.S., Mett I.L., et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 1998, 9:267-276.
30. Kang T.B., Ben-Moshe T., Varfolomeev E.E., Pewzner-Jung Y., Yogev N., Jurewicz A., et al. Caspase-8 serves both apoptotic and nonapoptotic roles. J Immunol 2004, 173:2976-2984.
31. Kang T.B., Oh G.-S., Scandella E., Bolinger B., Ludewig B., Kovalenko A., et al. Mutation of a self-processing site in caspase-8 compromises its apoptotic but not its nonapoptotic functions in bacterial artificial chromosome-transgenic mice. J Immunol 2008, 181:2522-2532.
32. Kovalenko A., Kim J.C., Kang T.B., Rajput A., Bogdanov K., Dittrich-Breiholz O., et al. Caspase-8 deficiency in epidermal keratinocytes triggers an inflammatory skin disease. J Exp Med 2009, 206:2161-2177.
33. Rajput A., Kovalenko A., Bogdanov K., Yang S.H., Kang T.B., Kim J.C., et al. RIG-I RNA helicase activation of IRF3 transcription factor is negatively regulated by caspase-8-mediated cleavage of the RIP1 protein. Immunity 2011, 34:340-351.
34. Kang T.B., Yang S.H., Toth B., Kovalenko A., Wallach D. Caspase-8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome. Immunity 2013, 38:27-40.